Project Grant R00HL163493
Award Date 8/1/26
Completion Date 6/30/29
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA 22904, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- The National Heart, Lung, and Blood Institute awarded Florida State University $703,101 on July 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to establish the role of structural elements in cardiac muscle contraction. The project addresses understudied functional regions of cardiac troponin C (CTNC), the calcium-binding subunit of the troponin complex that regulates calcium-dependent myofilament activation. The research targets cardiomyopathies arising from...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $721,977 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to uncover the molecular and functional organization of cardiovagal neurons that regulate heart rate through the vagus nerve. The project will map the synaptic inputs, outputs, and functional sufficiency of two distinct cardiovagal neuron subtypes—NPY2R-expressing neurons in the nucleus ambiguus and VIP-expressing neurons...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $760,465 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop deep learning methods that advance cardiac magnetic resonance strain imaging for personalized cardiac resynchronization therapy treatment planning. The award funds development of deep strain networks to rapidly and accurately predict myocardial displacements from cardiac magnetic resonance imaging, addressing...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $802,973 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop rapid point-of-care molecular imaging of immune activation in acute coronary syndrome and acute myocarditis using targeted microbubble contrast agents. The project applies myocardial contrast echocardiography with phosphatidylserine-incorporating lipid microbubbles (MB-PS) to detect inflammatory activation from...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $174,621 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance imaging (CMR) techniques for monitoring congenital heart disease using ultra-low field (ULF) MRI systems. The recipient will adapt CMR to an inexpensive, unshielded, open-geometry ULF MRI system and apply machine learning techniques to mitigate hardware limitations and...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $117,552 on January 4, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of lymphatic endothelial alpha globin in heart failure progression. The research examines how alpha globin expression in lymphatic endothelial cells mediates cardiac remodeling and chronic inflammation in cardiometabolic heart failure. Using genetically modified mice with inducible alpha globin...
- The National Heart, Lung, and Blood Institute awarded University of Massachusetts Medical School $103,686 on December 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support basic research into translation control mechanisms in heart and lung disease. The funded research investigates how the RNase A family nuclease angiogenin stimulates blood vessel formation and why angiogenin dysfunction associates with heart failure, and separately examines how the bacterial...
- The National Heart, Lung, and Blood Institute awarded The University of Texas Southwestern Medical Center $249,000 on February 16, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate metabolic remodeling driven by tachycardia and its role in cardiac dysfunction. Dr. Chengyi Tu will conduct a K99/R00 research project examining molecular signaling pathways underlying tachycardia-induced heart disease using induced pluripotent stem cell technology, engineered heart...
- The National Heart, Lung, and Blood Institute awarded $609,574 to the University of California, San Diego on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research into the cellular and molecular mechanisms regulating cardiac chamber morphology. The recipient is investigating how cardiomyocytes acquire distinct shapes and organizational patterns in the outer and inner curvatures of the embryonic ventricle, which establish proper cardiac chamber...